Nerinetide before reperfusion in acute ischaemic stroke: déjà vu or new insights?
- 20 February 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 395 (10227), 843-844
- https://doi.org/10.1016/s0140-6736(20)30316-0
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trialThe Lancet, 2020
- Poly-Arginine Peptide-18 (R18) Reduces Brain Injury and Improves Functional Outcomes in a Nonhuman Primate Stroke ModelNeurotherapeutics, 2019
- Stroke Treatment Academic Industry Roundtable XStroke, 2019
- Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammationThe Lancet Neurology, 2016
- Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trialsThe Lancet, 2016
- Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2012
- Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brainNature, 2012
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Effectiveness of PSD95 Inhibitors in Permanent and Transient Focal Ischemia in the RatStroke, 2008
- PDZ Protein Interactions Underlying NMDA Receptor-Mediated Excitotoxicity and Neuroprotection by PSD-95 InhibitorsJournal of Neuroscience, 2007